Clinical trial · Interventional
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Blood circulating endothelial cells (CEC) and microparticles (MPs) are described in the literature to be associated with vascular failures and dysfunction that reflect neo-angiogenesis and risk of thrombosis, respectively. There a few number of CEC in healthy patients although they significantly increase in several cancers including myeloma. However, no study explored to date a correlation of CEC and/or circulating endothelial progenitors (CEP) and MPs with the tumoral growth of monoclonal gammopathy. On the other hand, there is no study measuring the CEC and CEP directly in the bone marrow. The investigators aim is to evaluate these 2 original features in patients with monoclonal gammopathy: monoclonal gammopathy of undetermined signification (MGUS) and myeloma. This is a preliminary multicentric study.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Monoclonal Gammopathy | — | UNRESOLVED | — |
| Monoclonal Gammopathy of Undetermined Signification | — | UNRESOLVED | — |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood and bone marrow samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- monoclonal gamopathy
- description
- Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs. * Patient's age ≥18 yo, * Patients having signed the specific consent of the study.
- interventionNames
- Other: blood and bone marrow samples
Primary outcomes (3)
- measure
- Blood levels of CEC and its progenitors
- timeFrame
- Day 1
- description
- Blood levels of CEC and its progenitors
- measure
- Blood levels of soluble parameters of angiogenesis and of coagulability
- timeFrame
- Day 1
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs. * Patient's age ≥ 18 years old, * Patients having signed the specific consent of the study. Exclusion Criteria: * Treatment with chemotherapy and/or antiangiogenic drugs at the inclusion * Age \< 18 years old * No specific consent of the study
References
Publications (0)
Data not yet available